Used primarily in the development of targeted cancer therapies, this compound is a key component in the design of antibody-drug conjugates (ADCs). Its structure allows for the attachment of therapeutic agents to antibodies, enabling precise delivery to cancer cells while minimizing damage to healthy tissues. The PEG4 spacer enhances solubility and stability, improving the pharmacokinetic properties of the conjugate. It is particularly valuable in research focused on hematologic malignancies and solid tumors, offering a promising approach to enhance treatment efficacy and reduce side effects. Additionally, it is utilized in proteolysis-targeting chimeras (PROTACs) for targeted protein degradation, expanding its role in innovative therapeutic strategies.